First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: a pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales
<br><strong>Background<br></strong> Several countries restricted the administration of ChAdOx1 to older age groups in 2021 over safety concerns following case reports and observed versus expected analyses suggesting a possible association with cerebral venous sinus thrombosis...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Public Library of Science
2022
|
| _version_ | 1826277155665870848 |
|---|---|
| author | Kerr, S Joy, M Torabi, F Bedston, S Akbari, A Agrawal, U Beggs, J Bradley, D Chuter, A Docherty, AB Ford, D Hobbs, R Katikireddi, SV Lowthian, E de Lusignan, S Lyons, R Marple, J McCowan, C McGagh, D McMenamin, J Moore, E Murray, J-LK Owen, RK Pan, J Ritchie, L Shah, SA Shi, T Stock, S Tsang, RSM Vasileiou, E Woolhouse, M Simpson, CR Robertson, C Sheikh, A |
| author_facet | Kerr, S Joy, M Torabi, F Bedston, S Akbari, A Agrawal, U Beggs, J Bradley, D Chuter, A Docherty, AB Ford, D Hobbs, R Katikireddi, SV Lowthian, E de Lusignan, S Lyons, R Marple, J McCowan, C McGagh, D McMenamin, J Moore, E Murray, J-LK Owen, RK Pan, J Ritchie, L Shah, SA Shi, T Stock, S Tsang, RSM Vasileiou, E Woolhouse, M Simpson, CR Robertson, C Sheikh, A |
| author_sort | Kerr, S |
| collection | OXFORD |
| description | <br><strong>Background<br></strong>
Several countries restricted the administration of ChAdOx1 to older age groups in 2021 over safety concerns following case reports and observed versus expected analyses suggesting a possible association with cerebral venous sinus thrombosis (CVST). Large datasets are required to precisely estimate the association between Coronavirus Disease 2019 (COVID-19) vaccination and CVST due to the extreme rarity of this event. We aimed to accomplish this by combining national data from England, Scotland, and Wales.
<br><strong>
Methods and findings<br></strong>
We created data platforms consisting of linked primary care, secondary care, mortality, and virological testing data in each of England, Scotland, and Wales, with a combined cohort of 11,637,157 people and 6,808,293 person years of follow-up. The cohort start date was December 8, 2020, and the end date was June 30, 2021. The outcome measure we examined was incident CVST events recorded in either primary or secondary care records. We carried out a self-controlled case series (SCCS) analysis of this outcome following first dose vaccination with ChAdOx1 and BNT162b2. The observation period consisted of an initial 90-day reference period, followed by a 2-week prerisk period directly prior to vaccination, and a 4-week risk period following vaccination. Counts of CVST cases from each country were tallied, then expanded into a full dataset with 1 row for each individual and observation time period. There was a combined total of 201 incident CVST events in the cohorts (29.5 per million person years). There were 81 CVST events in the observation period among those who a received first dose of ChAdOx1 (approximately 16.34 per million doses) and 40 for those who received a first dose of BNT162b2 (approximately 12.60 per million doses). We fitted conditional Poisson models to estimate incidence rate ratios (IRRs). Vaccination with ChAdOx1 was associated with an elevated risk of incident CVST events in the 28 days following vaccination, IRR = 1.93 (95% confidence interval (CI) 1.20 to 3.11). We did not find an association between BNT162b2 and CVST in the 28 days following vaccination, IRR = 0.78 (95% CI 0.34 to 1.77). Our study had some limitations. The SCCS study design implicitly controls for variables that are constant over the observation period, but also assumes that outcome events are independent of exposure. This assumption may not be satisfied in the case of CVST, firstly because it is a serious adverse event, and secondly because the vaccination programme in the United Kingdom prioritised the clinically extremely vulnerable and those with underlying health conditions, which may have caused a selection effect for individuals more prone to CVST. Although we pooled data from several large datasets, there was still a low number of events, which may have caused imprecision in our estimates.
<br><strong>
Conclusions<br></strong>
In this study, we observed a small elevated risk of CVST events following vaccination with ChAdOx1, but not BNT162b2. Our analysis pooled information from large datasets from England, Scotland, and Wales. This evidence may be useful in risk–benefit analyses of vaccine policies and in providing quantification of risks associated with vaccination to the general public. |
| first_indexed | 2024-03-06T23:24:39Z |
| format | Journal article |
| id | oxford-uuid:69f318a8-9d36-48b5-a3a9-2d667802c04a |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:24:39Z |
| publishDate | 2022 |
| publisher | Public Library of Science |
| record_format | dspace |
| spelling | oxford-uuid:69f318a8-9d36-48b5-a3a9-2d667802c04a2022-03-26T18:54:32ZFirst dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: a pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and WalesJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:69f318a8-9d36-48b5-a3a9-2d667802c04aEnglishSymplectic ElementsPublic Library of Science2022Kerr, SJoy, MTorabi, FBedston, SAkbari, AAgrawal, UBeggs, JBradley, DChuter, ADocherty, ABFord, DHobbs, RKatikireddi, SVLowthian, Ede Lusignan, SLyons, RMarple, JMcCowan, CMcGagh, DMcMenamin, JMoore, EMurray, J-LKOwen, RKPan, JRitchie, LShah, SAShi, TStock, STsang, RSMVasileiou, EWoolhouse, MSimpson, CRRobertson, CSheikh, A<br><strong>Background<br></strong> Several countries restricted the administration of ChAdOx1 to older age groups in 2021 over safety concerns following case reports and observed versus expected analyses suggesting a possible association with cerebral venous sinus thrombosis (CVST). Large datasets are required to precisely estimate the association between Coronavirus Disease 2019 (COVID-19) vaccination and CVST due to the extreme rarity of this event. We aimed to accomplish this by combining national data from England, Scotland, and Wales. <br><strong> Methods and findings<br></strong> We created data platforms consisting of linked primary care, secondary care, mortality, and virological testing data in each of England, Scotland, and Wales, with a combined cohort of 11,637,157 people and 6,808,293 person years of follow-up. The cohort start date was December 8, 2020, and the end date was June 30, 2021. The outcome measure we examined was incident CVST events recorded in either primary or secondary care records. We carried out a self-controlled case series (SCCS) analysis of this outcome following first dose vaccination with ChAdOx1 and BNT162b2. The observation period consisted of an initial 90-day reference period, followed by a 2-week prerisk period directly prior to vaccination, and a 4-week risk period following vaccination. Counts of CVST cases from each country were tallied, then expanded into a full dataset with 1 row for each individual and observation time period. There was a combined total of 201 incident CVST events in the cohorts (29.5 per million person years). There were 81 CVST events in the observation period among those who a received first dose of ChAdOx1 (approximately 16.34 per million doses) and 40 for those who received a first dose of BNT162b2 (approximately 12.60 per million doses). We fitted conditional Poisson models to estimate incidence rate ratios (IRRs). Vaccination with ChAdOx1 was associated with an elevated risk of incident CVST events in the 28 days following vaccination, IRR = 1.93 (95% confidence interval (CI) 1.20 to 3.11). We did not find an association between BNT162b2 and CVST in the 28 days following vaccination, IRR = 0.78 (95% CI 0.34 to 1.77). Our study had some limitations. The SCCS study design implicitly controls for variables that are constant over the observation period, but also assumes that outcome events are independent of exposure. This assumption may not be satisfied in the case of CVST, firstly because it is a serious adverse event, and secondly because the vaccination programme in the United Kingdom prioritised the clinically extremely vulnerable and those with underlying health conditions, which may have caused a selection effect for individuals more prone to CVST. Although we pooled data from several large datasets, there was still a low number of events, which may have caused imprecision in our estimates. <br><strong> Conclusions<br></strong> In this study, we observed a small elevated risk of CVST events following vaccination with ChAdOx1, but not BNT162b2. Our analysis pooled information from large datasets from England, Scotland, and Wales. This evidence may be useful in risk–benefit analyses of vaccine policies and in providing quantification of risks associated with vaccination to the general public. |
| spellingShingle | Kerr, S Joy, M Torabi, F Bedston, S Akbari, A Agrawal, U Beggs, J Bradley, D Chuter, A Docherty, AB Ford, D Hobbs, R Katikireddi, SV Lowthian, E de Lusignan, S Lyons, R Marple, J McCowan, C McGagh, D McMenamin, J Moore, E Murray, J-LK Owen, RK Pan, J Ritchie, L Shah, SA Shi, T Stock, S Tsang, RSM Vasileiou, E Woolhouse, M Simpson, CR Robertson, C Sheikh, A First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: a pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales |
| title | First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: a pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales |
| title_full | First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: a pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales |
| title_fullStr | First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: a pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales |
| title_full_unstemmed | First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: a pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales |
| title_short | First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: a pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales |
| title_sort | first dose chadox1 and bnt162b2 covid 19 vaccinations and cerebral venous sinus thrombosis a pooled self controlled case series study of 11 6 million individuals in england scotland and wales |
| work_keys_str_mv | AT kerrs firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT joym firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT torabif firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT bedstons firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT akbaria firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT agrawalu firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT beggsj firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT bradleyd firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT chutera firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT dochertyab firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT fordd firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT hobbsr firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT katikireddisv firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT lowthiane firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT delusignans firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT lyonsr firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT marplej firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT mccowanc firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT mcgaghd firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT mcmenaminj firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT mooree firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT murrayjlk firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT owenrk firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT panj firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT ritchiel firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT shahsa firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT shit firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT stocks firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT tsangrsm firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT vasileioue firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT woolhousem firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT simpsoncr firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT robertsonc firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales AT sheikha firstdosechadox1andbnt162b2covid19vaccinationsandcerebralvenoussinusthrombosisapooledselfcontrolledcaseseriesstudyof116millionindividualsinenglandscotlandandwales |